TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 OVERVIEW OF GUATEMALA SPECIFIC POLLEN ALLERGIES MARKET 16
1.4 LIMITATIONS 18
1.5 MARKETS COVERED 18
2 MARKET SEGMENTATION 21
2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 23
2.4 CURRENCY AND PRICING 23
2.5 DBMR TRIPOD DATA VALIDATION MODEL 24
2.6 MULTIVARIATE MODELLING 27
2.7 PRODUCT TYPE LIFELINE CURVE 27
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
2.9 DBMR MARKET POSITION GRID 29
2.10 MARKET END USER COVERAGE GRID 30
2.11 VENDOR SHARE ANALYSIS 31
2.12 SECONDARY SOURCES 32
2.13 ASSUMPTIONS 32
3 EXECUTIVE SUMMARY 33
4 PREMIUM INSIGHTS 36
4.1 PESTEL ANALYSIS 37
4.2 PORTERS FIVE FORCES MODEL 38
4.3 CURRENT PATENTS THAT CAN BE USED IN ALLOPATHIC MEDICINES IN MEXICO- 39
4.4 INVENTION PATENT- 39
4.5 COUNTRY LEVEL ANALYSIS 40
5 REGULATIONS 42
5.1 GUATEMALA 42
6 MARKET OVERVIEW 43
6.1 DRIVERS 45
6.1.1 INCREASE IN PREVALENCE OF ALLERGIC DISORDER 45
6.1.2 WIDE RANGE OF PRODUCT PORTFOLIOS OFFERED BY MAJOR PLAYER 45
6.1.3 IMPACT OF POLLEN ALLERGIES ON PAEDIATRICS POPULATION 46
6.1.4 HEALTH SECTOR REFORM AND EXPANSION OF PROGRAMMES TO BOOST HEALTHCARE SPENDING 46
6.2 RESTRAINTS 47
6.2.1 SIDE EFFECTS ASSOCIATED WITH THE USE OF DRUGS 47
6.2.2 INCREASE IN TREND OF USING HOME REMEDIES/PHYTOCHEMICALS 47
6.3 OPPORTUNITIES 48
6.3.1 INCREASE IN THE ENVIRONMENTAL POLLUTION 48
6.3.2 AWARENESS OF THE USE OF OTC PRODUCTS 48
6.3.3 RELAXATION OF RULES ON DIRECT-TO-CONSUMER ADVERTISING 48
6.4 CHALLENGES 49
6.4.1 INCREASE IN ABUSE POTENTIAL 49
6.4.2 INTELLECTUAL PROPERTY RIGHTS LAW 50
7 GUATEMALA SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE 51
7.1 OVERVIEW 52
7.2 ANTIHISTAMINE 53
7.2.1 ANTIHISTAMINE, BY DRUG TYPE 54
7.2.2 LEVOCETIRIZINE 54
7.2.3 CETIRIZINE 54
7.2.4 LORATIDINE 55
7.2.5 DIPHENHYDRAMINE 55
7.2.6 CHLORPHENIRAMINE 55
7.2.7 FEXOFENADINE 56
7.3 CORTICOSTEROIDS 56
7.3.1 FLUTICASONE PROPIONATE 57
7.3.2 TRIAMCINOLONE/TRIAMCINOLONE ACETONOID 58
7.3.3 CROMOLYN SODIUM 58
7.3.4 OTHERS 58
7.4 DECONGESTANTS 59
7.4.1 DECONGESTANTS, BY DRUG TYPE 59
7.4.2 PSEUDOEPHEDRINE 60
7.4.3 PHENYLEPHRINE 60
7.4.4 OXYMETAZOLINE 61
7.4.5 OTHERS 61
7.5 ANTICHOLINERGICS 61
7.5.1 ANTICHOLINERGICS, BY DRUG TYPE 62
7.5.2 IPRATROPIUM BROMIDE 62
7.5.3 OTHERS 63
7.6 OTHERS 63
8 GUATEMALA SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS 64
8.1 OVERVIEW 65
8.2 INSTRUMENTS 66
8.2.1 IMMUNO ASSAY ANALYZER 67
8.2.2 PRODUCTS, BY IMMUNOASSAY ANALYZER 68
8.3 RADIO IMMUNO ASSAY (RIA) 68
8.4 COUNTING IMMUNO ASSAY (CIA) 68
8.5 ENZYME LINKED IMMUNO-SORBENT ASSAYS (ELISA) 69
8.6 FLUOROIMMNOASSAY (FIA) 69
8.7 CHEMILUMINESCENCE ASSAY 70
8.7.1 LUMINOMETERS 70
8.8 REAGENTS AND KITS 70
8.9 OTHERS 71
9 GUATEMALA SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST 72
9.1 OVERVIEW 73
9.2 IN VIVO TEST 74
9.2.1 IN VIVO TEST, BY DIAGNOSTIC TEST 74
9.2.2 SKIN PRICK 75
9.2.2.1 SKIN PRICK, BY DIAGNOSTIC TEST 75
9.2.2.2 GREER PRICK 76
9.2.3 THE STELLAR POINT 76
9.2.4 PHAZET 76
9.2.5 BIFURCATED SMALLPOX VACCINATION TEST 76
9.2.6 23G INTRAVENOUS NEEDLE 77
9.2.7 OTHERS 77
9.2.8 PATCH TEST 77
9.2.9 INTRADERMAL TEST 78
9.3 IN VITRO TEST 78
9.3.1 IN VITRO TEST, BY DIAGNOSTIC TEST 79
9.3.2 SERUM SPECIFIC IGE ASSAY 79
9.3.3 TOTAL IGE ASSAY 79
9.3.4 BASOPHIL ACTIVATION TEST 80
10 GUATEMALA SPECIFIC POLLEN ALLERGIES MARKET, BY END USER 81
10.1 OVERVIEW 82
10.2 HOSPITALS 83
10.3 DIAGNOSTICS LABORATORIES 83
10.4 ACADEMIC AND RESEARCH INSTITUTES 84
10.5 OTHERS 85
11 GUATEMALA SPECIFIC POLLEN ALLERGIES MARKET, BY DISTRIBUTION CHANNEL 86
11.1 OVERVIEW 87
11.2 DIRECT TENDER 88
11.3 RETAIL SALES 88
11.3.1 RETAIL SALES, BY TYPE 89
11.3.2 HOSPITAL PHARMACY 89
11.3.3 RETAIL PHARMACY 89
11.3.4 ONLINE PHARMACY 90
12 GUATEMALA SPECIFIC POLLEN ALLERGIES MARKET: COMPANY LANDSCAPE 91
12.1 COMPANY SHARE ANALYSIS: GUATEMALA SPECIFIC POLLEN ALLERGIES MARKET 91
13 SWOT ANALYSIS 92
14 COMPANY PROFILE 93
14.1 GLAXOSMITHKLINE PLC 93
14.1.1 COMPANY SNAPSHOT 93
14.1.2 REVENUE ANALYSIS 93
14.1.3 PRODUCT PORTFOLIO 94
14.1.4 RECENT DEVELOPMENTS 94
14.2 JOHNSON & JOHNSON SERVICES, INC 95
14.2.1 COMPANY SNAPSHOT 95
14.2.2 REVENUE ANALYSIS 95
14.2.3 PRODUCT PORTFOLIO 96
14.2.4 RECENT DEVELOPMENTS 96
14.3 PERRIGO COMPANY PLC 97
14.3.1 COMPANY SNAPSHOT 97
14.3.2 REVENUE ANALYSIS 97
14.3.3 PRODUCT PORTFOLIO 98
14.3.4 RECENT DEVELOPMENTS 98
14.4 SIEMENS HEALTHCARE GMBH 99
14.4.1 COMPANY SNAPSHOT 99
14.4.2 REVENUE ANALYSIS 99
14.4.3 PRODUCT PORTFOLIO 100
14.4.4 RECENT DEVELOPMENTS 100
14.5 THERMO FISHER SCIENTIFIC INC. 101
14.5.1 COMPANY SNAPSHOT 101
14.5.2 REVENUE ANALYSIS 101
14.5.3 PRODUCT PORTFOLIO 102
14.5.4 RECENT DEVELOPMENT 102
14.6 BAYER AG 103
14.6.1 COMPANY SNAPSHOT 103
14.6.2 REVENUE ANALYSIS 103
14.6.3 PRODUCT PORTFOLIO 104
14.6.4 RECENT DEVELOPMENT 104
14.7 ALCON INC. 105
14.7.1 COMPANY SNAPSHOT 105
14.7.2 REVENUE ANALYSIS 105
14.7.3 PRODUCT PORTFOLIO 106
14.7.4 RECENT DEVELOPMENTS 106
14.8 BIOMRIEUX, SA. 107
14.8.1 COMPANY SNAPSHOT 107
14.8.2 REVENUE ANALYSIS 107
14.8.3 PRODUCT PORTFOLIO 108
14.8.4 RECENT DEVELOPMENTS 108
14.9 CINFA LABORATORIES 109
14.9.1 COMPANY SNAPSHOT 109
14.9.2 PRODUCT PORTFOLIO 109
14.9.3 RECENT DEVELOPMENT 109
14.10 CIRCASSIA 110
14.10.1 COMPANY SNAPSHOT 110
14.10.2 REVENUE ANALYSIS 110
14.10.3 PRODUCT PORTFOLIO 111
14.10.4 RECENT DEVELOPMENTS 111
14.11 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG 112
14.11.1 COMPANY SNAPSHOT 112
14.11.2 PRODUCT PORTFOLIO 112
14.11.3 RECENT DEVELOPMENTS 113
14.12 LINCOLN DIAGNOSTICS, INC. 114
14.12.1 COMPANY SNAPSHOT 114
14.12.2 PRODUCT PORTFOLIO 114
14.12.3 RECENT DEVELOPMENTS 114
14.13 MINARIS MEDICAL AMERICA, INC. 115
14.13.1 COMPANY SNAPSHOT 115
14.13.2 PRODUCT PORTFOLIO 115
14.13.3 RECENT DEVELOPMENTS 115
14.14 PRESTIGE CONSUMER HEALTHCARE INC. 116
14.14.1 COMPANY SNAPSHOT 116
14.14.2 REVENUE ANALYSIS 116
14.14.3 PRODUCT PORTFOLIO 117
14.14.4 RECENT DEVELOPMENT 117
14.15 QUEST DIAGNOSTICS INCORPORATED 118
14.15.1 COMPANY SNAPSHOT 118
14.15.2 REVENUE ANALYSIS 118
14.15.3 PRODUCT PORTFOLIO 119
14.15.4 RECENT DEVELOPMENT 119
14.16 SANOFI 120
14.16.1 COMPANY SNAPSHOT 120
14.16.2 REVENUE ANALYSIS 120
14.16.3 PRODUCT PORTFOLIO 121
14.16.4 RECENT DEVELOPMENTS 121
15 QUESTIONNAIRE 122
16 RELATED REPORTS 125

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.